Enavate's Zenas Pharma Footnote: Obexelimab Pipeline Watch
Inside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
For beginners, compare index funds and mutual funds on cost, simplicity, and diversification to choose the easier path to investing.
24,324 articlesInside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
Two big reasons explain why the fear around IBM's COBOL future might be overstated. This piece breaks down why COBOL ...
MP Materials is capturing attention as the only fully integrated u.s. rare earth producer. With buzz around potential...
As AI models scale, the memory layer becomes the bottleneck that can shape profits. This piece explains why sandisk (...
Brookfield plans value per share offers a long‑term lens on value. This guide explains the metric, how it links to th...
A surprising analyst upgrade helped StubHub Holdings stock crush expectations this week. This article breaks down the...
Investors cheered a decisive move higher as Okta unveiled AI-powered growth opportunities. The stock touched a new 52...
Two real estate giants are dueling over how data is distributed. As Compass leans on MLS access to push its agenda, o...
Artificial intelligence isn’t just software. It’s a hardware race that powers every smart AI system. This tech stock ...
Retirees who claimed social security here’s at 62 may still see bigger monthly checks later, thanks to a do-over rule...
Meta Platforms is accelerating its real-time ai push, aiming to turn data streams into immediate monetization. With 2...
Toss teams with Poseidon to turn its 30 million users into contributors for AI training, launching Numo inside the To...